-- Scott Roberts
MONDAY, Oct. 24 (HealthDay News) -- The first generic versions
of Zyprexa (olanzapine) have been approved by the U.S. Food and
Drug Administration to treat schizophrenia or bipolar disorder, the
agency said Monday.
Olanzapine has a boxed label warning that the drug can cause
death among elderly people who have psychosis due to confusion and
memory loss, the FDA said in a news release. Other serious adverse
reactions could include high blood sugar, high cholesterol or
triglycerides, and weight gain.
Schizophrenia is a brain disorder that affects about 1 percent
of Americans, with symptoms including hearing voices, paranoia,
being suspicious and withdrawing from everyday life. Bipolar
disorder, also known as manic-depressive illness, includes symptoms
such as unusual changes in mood, energy and ability to perform
The agency said any generic drugs it approves are clinically
equivalent to the brand-name versions in quality, strength, purity
Approval to produce generic versions of olanzapine were given
to: Dr. Reddy's Laboratories Ltd., Teva Pharmaceuticals USA, Apotex
Inc. and Par Phamaceuticals Inc.
The FDA has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.